<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00288366</url>
  </required_header>
  <id_info>
    <org_study_id>050942</org_study_id>
    <secondary_id>NARSAD</secondary_id>
    <nct_id>NCT00288366</nct_id>
  </id_info>
  <brief_title>Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome</brief_title>
  <official_title>Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the effect of various mood stabilizers (MS) on
      the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in
      patients treated with antipsychotic drugs (APDs). Patients will be switched from their
      current antipsychotic medication to aripiprazole (Abilify) or ziprasidone (Geodon) (unless
      clinically contraindicated) for comparison with metabolic levels during treatment with the
      former medication.

      The metabolic syndrome is an empirical concept based on extensive evidence that a
      constellation of 5 metabolic abnormalities, e.g. increased cholesterol, hypertension, low
      HDL, taken together, predict marked increases in the risk of CVD, stroke and some types of
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HDL Ratio</measure>
    <time_frame>24 weeks from Baseline</time_frame>
    <description>change in HDL ratio after medication switch</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aripiprazole (Abilify)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ziprasidone (Geodon)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ziprasidone vs. aripiprazole</intervention_name>
    <description>ziprasidone vs. aripiprazole dosed according to package insert</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aripiprazole vs. ziprasidone</intervention_name>
    <description>aripiprazole vs. ziprasidone dosed according to package insert</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        To be eligible, patients must :

          -  Be male or female, age 18-65

          -  Be diagnosed with schizophrenia, schizoaffective disorder or bipolar disorder with
             psychotic features according to DSM-IV criteria

          -  Be currently receiving antipsychotic drugs (clozapine, haloperidol, olanzapine,
             quetiapine, or risperidone) (APDs) alone, mood stabilizer(s) (MS) alone, or a
             combination of the two

          -  Have a history of compliance with the above medication

          -  Have presumptive IRS as indicated by a TG/HDL ratio &gt; 3.5 on current antipsychotic
             medication

          -  Be Medicaid eligible or maintain insurance covering requested lab procedures

          -  Be able to provide written informed consent Exclusion criteria

        A patient will be considered ineligible if he/she:

          -  Has a diagnosis other than schizophrenia, schizoaffective disorder or bipolar disorder
             with psychotic features according to DSM-IV criteria.

          -  Has a history of noncompliance with prescribed psychiatric medications

          -  Has a TG/HDL ratio &lt; 3.5 on current medication

          -  Is uninsured or is unable to self-pay potential costs of required lab procedures not
             covered by insurance.

          -  Is unable to provide written informed consent.

          -  (Females only) Is pregnant, lactating or plans to become pregnant during study
             participation

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuejin Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychiatric Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 6, 2006</study_first_submitted>
  <study_first_submitted_qc>February 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2006</study_first_posted>
  <results_first_submitted>May 24, 2017</results_first_submitted>
  <results_first_submitted_qc>July 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2019</results_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Herbert Meltzer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>schizoaffective disorder</keyword>
  <keyword>bipolar disorder</keyword>
  <keyword>metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aripiprazole</title>
          <description>aripiprazole (Abilify)
ziprasidone vs. aripiprazole: ziprasidone vs. aripiprazole dosed according to package insert
aripiprazole vs. ziprasidone: aripiprazole vs. ziprasidone dosed according to package insert</description>
        </group>
        <group group_id="P2">
          <title>Ziprasidone</title>
          <description>ziprasidone (Geodon)
aripiprazole vs. ziprasidone: aripiprazole vs. ziprasidone dosed according to package insert</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole</title>
          <description>aripiprazole (Abilify)
ziprasidone vs. aripiprazole: ziprasidone vs. aripiprazole dosed according to package insert
aripiprazole vs. ziprasidone: aripiprazole vs. ziprasidone dosed according to package insert</description>
        </group>
        <group group_id="B2">
          <title>Ziprasidone</title>
          <description>ziprasidone (Geodon)
aripiprazole vs. ziprasidone: aripiprazole vs. ziprasidone dosed according to package insert</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.3" spread="8.5"/>
                    <measurement group_id="B2" value="45.5" spread="9.4"/>
                    <measurement group_id="B3" value="44.9" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HDL Ratio</title>
        <description>change in HDL ratio after medication switch</description>
        <time_frame>24 weeks from Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>aripiprazole (Abilify)
ziprasidone vs. aripiprazole: ziprasidone vs. aripiprazole dosed according to package insert
aripiprazole vs. ziprasidone: aripiprazole vs. ziprasidone dosed according to package insert</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone</title>
            <description>ziprasidone (Geodon)
aripiprazole vs. ziprasidone: aripiprazole vs. ziprasidone dosed according to package insert</description>
          </group>
        </group_list>
        <measure>
          <title>HDL Ratio</title>
          <description>change in HDL ratio after medication switch</description>
          <units>unit of Measure ''g/dL''</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7" spread="1.6"/>
                    <measurement group_id="O2" value="38.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" spread="2.1"/>
                    <measurement group_id="O2" value="42.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aripiprazole</title>
          <description>aripiprazole (Abilify)
ziprasidone vs. aripiprazole: ziprasidone vs. aripiprazole dosed according to package insert
aripiprazole vs. ziprasidone: aripiprazole vs. ziprasidone dosed according to package insert</description>
        </group>
        <group group_id="E2">
          <title>Ziprasidone</title>
          <description>ziprasidone (Geodon)
aripiprazole vs. ziprasidone: aripiprazole vs. ziprasidone dosed according to package insert</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of psychiatric symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Herbert Y Meltzer</name_or_title>
      <organization>Northwestern University</organization>
      <phone>1 312 503 0309</phone>
      <email>h-meltzer@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

